Skin rash with pink-red blotches especially on palms of hands or soles of feet which may blister Muscle weakness, tenderness or pain and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown which can be life-threatening and lead to kidney problems.
If you experience problems with unexpected or unusual bleeding or bruising, this may be suggestive of a liver complaint.
You should consult your doctor as soon as possible. Other possible side effects with Atorvastatin tablets: Common side effects may affect up to 1 in 10 people include: Uncommon side effects may affect up to 1 in people include: Rare side effects may affect up to 1 in people include: Very rare side effects may affect up to 1 in 10, people include: Not known cannot be estimated from the available data: Muscle weakness that is constant Possible side effects reported with some statins medicines of the same type: This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.
Your doctor will monitor you while you are taking this medicine. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. You can also report side effects directly via the Yellow Card Scheme at: This medicine does not require any special storage conditions. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Each 10mg, 20mg or 40mg film-coated tablet contains 10mg, 20mg or 40mg respectively of atorvastatin. The other ingredients are: It belongs to a class of drugs referred to as statins, which includes lovastatin Mevacor , simvastatin, Zocor , fluvastatin Lescol , and pravastatin Pravachol and rosuvastatin Crestor.
All statins, including atorvastatin, prevent the production of cholesterol in the liver by blocking HMG-CoA reductase, an enzyme that makes cholesterol. Statins reduce total cholesterol as well as LDL cholesterol in blood. LDL cholesterol is believed to be the "bad" cholesterol that is primarily responsible for the development of coronary artery disease.
Reducing LDL cholesterol levels retards progression and may even reverse coronary artery disease. Atorvastatin also raises the concentrations of HDL "good" cholesterol that protects against coronary artery disease and reduces the concentration of triglycerides in the blood. High blood concentrations of triglycerides also have been associated with coronary artery disease.
The FDA approved atorvastatin in December Interaction studies evaluating the effects of amiodarone or verapamil on atorvastatin have not been conducted. Both amiodarone and verapamil are known to inhibit CYP3A4 activity and co-administration with atorvastatin may result in increased exposure to atorvastatin.
Therefore, a lower maximum dose of atorvastatin should be considered and appropriate clinical monitoring of the patient is recommended when concomitantly used with moderate CYP3A4 inhibitors. Appropriate clinical monitoring is recommended after initiation or following dose adjustments of the inhibitor.
Due to the dual interaction mechanism of rifampin, cytochrome P 3A induction and inhibition of hepatocyte uptake transporter OATP1B1 , simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
The effect of rifampin on atorvastatin concentrations in hepatocytes is, however, unknown and if concomitant administration cannot be avoided, patients should be carefully monitored for efficacy. Transport protein inhibitors Inhibitors of transport proteins e. The effect of inhibition of hepatic uptake transporters on atorvastatin concentrations in hepatocytes is unknown.
If concomitant administration cannot be avoided, a dose reduction and clinical monitoring for efficacy is recommended see Table 1.
The risk of these events may be increased with concomitant use of fibric acid derivatives and atorvastatin. If concomitant administration cannot be avoided, the lowest dose of atorvastatin to achieve the therapeutic objective should be used and the patients should be appropriately monitored see section 4.
Ezetimibe The use of ezetimibe alone is associated with muscle related events including rhabdomyolysis. The risk of these events may therefore be increased with concomitant use of ezetimibe and atorvastatin. Appropriate clinical monitoring of the patients is recommended. However, lipid effects were greater when Atorvastatin Mylan and colestipol were co-administered than when either medicinal product was given alone.
Fusidic acid The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction whether it is pharmacodynamic or pharmacokinetic, or both is yet unknown.
There have been reports of rhabdomyolysis including some fatalities in patients receiving this combination. If treatment with systemic fusidic acid is necessary, atorvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment see section 4. Colchicine Although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.
Effect of atorvastatin on co-administered medicinal products Digoxin When multiple doses of digoxin and 10 mg atorvastatin were co-administered, steady-state digoxin concentrations increased slightly. Patients taking digoxin should be monitored appropriately. Oral Contraceptives Co-administration of Atorvastatin Mylan with an oral contraceptive produced increases in plasma concentrations of norethindrone and ethinyl oestradiol.
Warfarin In a clinical study in patients receiving chronic warfarin therapy, co-administration of atorvastatin 80 mg daily with warfarin caused a small decrease of about 1. Atorvastatina Kern Pharma reviews Read drug prescription It is very important to know about what medicine is given by the doctor, for what condition, and when it needs to be taken in what dose.
This information given by the doctor is called Prescription. The patients should be familiar with the medicine prescription, and the details about the medicine before purchasing it and using it. Some medications need not be prescribed by healthcare practitioners and can be purchased and used without prescription by the patients; these are called over-the-counter medications. Read the drug prescription information of Atorvastatina Kern Pharma before taking it.
Concomitant treatment with other medicinal products Risk of rhabdomyolysis is increased when atorvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of atorvastatin such as potent inhibitors of Atorvastatin or transport proteins e. If treatment with systemic fusidic acid is necessary, atorvastatin 1a pharma 10mg, atorvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment. See more information regarding rhabdomyolysis in section 4 Other medicines to regulate lipid levels, e. Each daily dose of atorvastatin is given all at once and may be given at any time of day with or without food. If concomitant 10mg how to buy finasteride be avoided, a dose reduction and clinical monitoring for efficacy is recommended see Table 1. Usual Adult Dose for Hyperlipidemia: Atorvastatin 1A Pharma contains the following excipients: The release specification includes the check of all parameters relevant to this pharmaceutical form. This medicine does not require any special storage conditions. Appropriate data concerning the control of the finished product support the compliance with the release specifications. If you stop taking Atorvastatin pharma If you have any further questions on the use of this medicine or wish to stop your treatment, atorvastatin 1a pharma 10mg, ask your doctor or pharmacist. Creatine kinase ulipristal acetate levonorgestrel Creatine kinase CK should not pharma measured following strenuous exercise or in the presence of any plausible 10mg cause of CK increase as this atorvastatin value interpretation difficult. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. For patients with prior hemorrhagic stroke or lacunar infarct, the balance of risks and benefits of atorvastatin 80 mg is uncertain, and the potential risk of hemorrhagic stroke should be carefully considered before initiating treatment see section 5. Both amiodarone and verapamil are known to inhibit CYP3A4 activity and co-administration with atorvastatin may result in increased exposure to atorvastatin, atorvastatin 1a pharma 10mg.
Tags: flomax 350mg bustina cla 45 amg 0-100 mph order oxycodone overseas
© Copyright 2017 Atorvastatin 1a pharma 10mg / myminecraft1.azurewebsites.net.